Special Investigation For RCC Of Sutent (Regulatory Post Marketing Commitment Plan).
Phase of Trial: Phase IV
Latest Information Update: 20 Jan 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 20 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 30 Oct 2014 Planned number of patients changed from 600 to 400, as reported by ClinicalTrials.gov record.